International Journal of Medical and Pharmaceutical Sciences
Open access peer-reviewed Journal
Volume 2, Issue 6, Page 155-168.
https://doi.org/10.5281/zenodo.20676011

Review Article

A Review on Transdermal Drug Delivery System

Prerna Jagne*, Minakshi Warghane

Department of Pharmacy, Mouda College of Pharmacy, Mouda

Transdermal drug delivery system (TDDS) represents a controlled and non-invasive approach for delivering drugs through the skin into systemic circulation. This system offers several advantages over conventional dosage forms, including avoidance of hepatic first-pass metabolism, improved patient compliance, sustained drug release, and reduced dosing frequency. The skin, particularly the stratum corneum, acts as the principal barrier for transdermal permeation; therefore, understanding skin anatomy and absorption pathways is essential for effective patch design. Drugs may penetrate the skin via transcellular, intercellular, or appendageal routes. Various patch designs such as matrix, reservoir, and micro-reservoir systems have been developed to control drug release. Recent advancements including microneedle-based patches and smart transdermal systems have significantly expanded the scope of TDDS. This review systematically compiles and analyzes information from multiple research articles to discuss skin anatomy, absorption mechanisms, factors affecting permeation, patch components, types of transdermal systems, and recent technological advancements. Transdermal drug delivery systems (TDDS) represent a significant advancement in pharmaceutical technology, offering a non-invasive alternative to traditional oral and parenteral routes. These systems involve medicated adhesive patches designed to deliver therapeutic agents through the skin and into the systemic circulation at a controlled rate. This review provides a comprehensive analysis of skin anatomy, the fundamental mechanisms of drug permeation, and the essential components of transdermal patches. Furthermore, it explores the biological and physicochemical factors influencing drug absorption and highlights recent technological breakthroughs, such as microneedles, aimed at enhancing delivery efficiency.

Keywords: Transdermal patch; Skin permeability; Drug absorption; Matrix system; Microneedles; Controlled drug delivery TDDS, Stratum corneum, Percutaneous absorption, Permeation enhancers, Controlled release, First-pass metabolism.

INTRODUCTION

The transdermal drug delivery system (TDDS) is an advanced and controlled drug delivery approach designed to deliver therapeutically effective drug concentrations across the skin into the systemic circulation. Over the past few decades, TDDS has emerged as a promising alternative to conventional drug delivery routes such as oral and parenteral administration. Although the oral route is the most commonly used method for drug administration, it is often associated with several limitations including gastrointestinal degradation of drugs, poor bioavailability, hepatic first-pass metabolism, frequent dosing, and patient non-compliance. Parenteral routes, on the other hand, are invasive, painful, and may lead to reduced patient acceptance, particularly in long-term therapy.[1-3] Transdermal drug delivery overcomes many of these drawbacks by providing a non-invasive, painless, and convenient method of drug administration. In TDDS, drugs are administered in the form of patches that are applied to the surface of the skin, from where the drug is released in a controlled manner and absorbed into the systemic circulation.[3] This approach allows maintenance of relatively constant plasma drug concentrations over an extended period of time, thereby minimizing peak-and-trough fluctuations associated with conventional dosage forms. As a result, TDDS improves therapeutic efficacy while reducing adverse effects.[3-6]

The skin, being the largest organ of the human body, serves as both a protective barrier and a potential route for drug delivery. However, the presence of the stratum corneum in the epidermis poses a major challenge to transdermal drug permeation. Only drugs with suitable physicochemical properties such as low molecular weight, appropriate lipophilicity, and adequate potency are considered ideal candidates for transdermal delivery. Therefore, a thorough understanding of skin anatomy, drug absorption pathways, and factors influencing skin permeability is essential for the successful design of transdermal formulations.[1-4] Various formulation strategies have been employed to enhance transdermal drug permeation, including the use of polymers, penetration enhancers, and novel delivery systems. Transdermal patches are broadly classified into matrix-type, reservoir-type, and micro-reservoir systems based on their design and drug release mechanism. Each type offers distinct advantages in controlling drug release and improving patient compliance. In recent years, technological advancements such as microneedle-based patches, iontophoresis, and smart transdermal systems have further expanded the scope of TDDS, enabling the delivery of macromolecules and biologics through the skin.[2-5] The present review aims to provide a comprehensive and systematic overview of transdermal drug delivery systems with emphasis on skin anatomy, mechanisms of drug absorption, factors affecting transdermal permeation, types and components of transdermal patches, pharmaceutical applications, and recent advances in transdermal technology. This review is intended to serve as a useful academic reference for undergraduate and postgraduate pharmacy students as well as

1) Anatomy of Skin Related To Transdermal Absorption

The skin is the largest organ of the human body, covering approximately 1.5–2.0 m² and accounting for nearly 7% of total body weight. Structurally, it consists of three major layers: epidermis, dermis, and hypodermis. Each layer plays a significant role in regulating drug permeation.[5]

1.1 Epidermis

The epidermis is the outermost layer composed mainly of keratinized stratified squamous epithelium. The stratum corneum, the outermost sub-layer, is the principal barrier to drug penetration. It consists of dead keratinocytes embedded in a lipid matrix, restricting the passage of most hydrophilic and large molecular weight drugs.[1-5]

1.2 Dermis

The dermis is a vascular connective tissue layer containing blood vessels, lymphatics, nerves, hair follicles, and sweat glands. It provides nutrients and acts as a sink for drugs that have crossed the epidermis, thereby maintaining a concentration gradient necessary for continuous permeation.[1-5]

1.3 Hypodermis

The hypodermis consists mainly of adipose tissue and serves as mechanical protection and thermal insulation. While it does not significantly influence drug permeation, it supports the dermis and epidermis structurally.[1-8]



Fig 1: - Transdermal drug absorption pathways

2. Mechanism Of Drug Absorption Through Skin

Drug molecules penetrate the skin through three major pathways:

2.1 Transcellular Pathway

In this route, drugs pass directly through the corneocytes. This pathway is mainly followed by small, moderately lipophilic molecules.[9]

2.2 Intercellular Pathway

This is the predominant route of penetration, where drugs diffuse through the lipid matrix between corneocytes. Most transdermal drugs utilize this pathway due to its relatively larger surface area.[2-9]

2.3 Appendageal Pathway

Drugs permeate through hair follicles and sweat glands. Although this route contributes minimally due to limited surface area, it is significant for ions and large polar molecules.[2-10]



Fig 2: - Transdermal drug delivery pathways

3. Factors Affecting Transdermal Drug Absorption

Transdermal drug absorption is influenced by several interrelated factors. These factors can be broadly classified into physicochemical properties of the drug, biological factors related to the skin, and formulation-related factors. Proper optimization of these parameters is essential for the successful development of an effective transdermal patch.

3.1 Physicochemical Factors

The physicochemical characteristics of a drug play a crucial role in determining its suitability for transdermal delivery.

Molecular Weight:

Drugs with low molecular weight (generally below 500 Da) permeate the skin more easily compared to large molecules.

Partition Coefficient:

An ideal transdermal drug should possess balanced lipophilicity and hydrophilicity. Excessively lipophilic drugs may remain in the stratum corneum, whereas highly hydrophilic drugs may fail to penetrate the lipid-rich barrier.

Melting Point:

Drugs with lower melting points exhibit higher solubility and improved permeation through the skin.

Drug Concentration:

An increased drug concentration enhances the diffusion rate by maintaining a higher concentration gradient across the skin.[1-7]

3.2 Biological Factors

Biological characteristics of the skin significantly influence transdermal absorption.

Skin Condition:

Damaged or hydrated skin shows higher permeability compared to dry and intact skin.

Age:

Skin permeability is higher in infants and elderly individuals due to thinner stratum corneum.

Skin Site:

Different anatomical sites exhibit variable permeability. Areas with thin stratum corneum, such as behind the ear, show enhanced absorption.

Blood Flow:

Increased blood circulation enhances systemic uptake of drugs after permeation.[2-5]

3.3 Formulation-Related Factors

Formulation design greatly affects drug release and permeation.

Type of Polymer:

Selection of polymer determines drug release rate and mechanical strength of the patch.

Natural polymer: -

1. Chitosan
2. sodium alginate
3. gelatin
4. starch
5. cellulose, etc

Natural polymer are biocompatible and biodegradable

Semi-synthetic polymers	Synthetic polymers
HPMC (Hydroxypropyl methylcellulose)	PVA (Polyvinyl alcohol)
Ethyl cellulose	PVP (Polyvinyl pyrrolidone)
CMC (Carboxymethyl cellulose)	Eudragit (RL, RS, L, S)
HPC	PEG (Polyethylene glycol)
etc	PLA, PLGA, etc

:- semi-synthetic polymers are common for controlled drug release.
:- synthetic polymers are strong, stable, long-term release.

Penetration Enhancers:

Penetration enhancers are agents that temporarily and reversibly increase the permeability of the skin to allow greater transport of drugs across the skin without causing permanent damage.

Mechanism of Action

Penetration enhancers work by:

1. Disrupting lipid structure of the stratum corneum
2. Increasing skin hydration
3. Altering protein structure
4. Increasing drug solubility in skin.

Chemical Enhancers	Surfactant	Terpenes
Dimethyl sulfoxide (DMSO)	Sodium lauryl sulfate	Menthol
Ethanol	Tween 80	Limonene
Propylene glycol	Span 20	Eugenol
Oleic acid	Brij 35	Camphor
Isopropyl myristate	Cetyltrimethylammonium bromide	1,2-Cineole (Eucalyptol)

Ideal Characteristics of Penetration Enhancers

1. Non-toxic

It should not show any toxic effect on the skin or systemic circulation, even after repeated application.

2. Non-irritant and Non-allergenic

It should not cause skin irritation, redness, itching, burning sensation, or allergic reactions.

3. Reversible Action

The effect of the penetration enhancer on skin permeability should be temporary, and the skin should return to its normal barrier function after removal.

4. No Permanent Skin Damage

It should not cause permanent damage to the stratum corneum, epidermis, or dermis.

5. Pharmacologically Inert

It should not possess any pharmacological activity of its own and should not interfere with the therapeutic action of the drug.

6. Compatible with Drug and Polymer

It should be chemically and physically compatible with the drug, polymer, and other excipients used in the formulation.

7. Effective at Low Concentration

It should enhance skin penetration even at low concentrations to minimize the risk of irritation and toxicity.

8. No Effect on Drug Stability

It should not cause degradation, precipitation, or instability of the drug.

9. Good Solvent Properties

It should increase drug solubility in the skin and formulation, thereby improving drug diffusion.

10. Acceptable Odour and Appearance

It should be cosmetically acceptable, with no unpleasant smell or discoloration.

11. Easy to Formulate

It should be easy to incorporate into transdermal patches, gels, or ointments without affecting formulation properties.[1-9]

Patch Thickness:

Thicker patches may retard drug release, whereas thinner patches allow faster diffusion. Patch thickness is an important physical parameter of a transdermal patch that directly affects drug release, mechanical strength, flexibility, and patient comfort.

Importance of Patch Thickness

1. Uniform Drug Distribution

Uniform thickness ensures equal distribution of drug throughout the patch.

2. Controlled Drug Release

Increased thickness results in slower drug release, whereas decreased thickness leads to faster drug release.

3. Mechanical Strength

Proper thickness provides sufficient strength and prevents breaking or tearing of the patch during handling.

4. Flexibility and Patient Comfort

Very thick patches may be uncomfortable, while very thin patches may lack durability.

5. Batch-to-Batch Reproducibility

Uniform thickness ensures consistency between different batches of patches.

6. Dose Accuracy

Patch thickness directly affects the amount of drug per unit area. Uniform thickness ensures accurate and consistent dosing, which is essential for therapeutic effectiveness and patient safety.

Factors Affecting Patch Thickness

- Polymer concentration
- Amount of drug and plasticizer
- Volume of solvent used
- Area of casting surface
- Drying temperature and time

Measurement of Patch Thickness

Patch thickness is measured at 3–5 different points using:

1. Vernier caliper
2. Digital micrometer screw gauge

The average thickness is calculated and reported.

Ideal Thickness Range

Generally, 0.1 – 1.0 mm, depending on formulation and polymer type.

4. Types Of Transdermal Drug Delivery Systems

Based on design and drug release mechanism, transdermal patches are classified into various types.

4.1 Matrix-Type Transdermal Patches

Matrix-type transdermal patches are one of the most commonly used designs in transdermal drug delivery systems, where the drug is uniformly dispersed within a polymer matrix that controls drug release.

Basic Structure

A matrix-type transdermal patch generally consists of:

1. Backing layer – protects the patch from the external environment
2. Drug-polymer matrix – contains drug uniformly dispersed in polymer
3. Adhesive layer – helps the patch stick to the skin (may be part of matrix)
4. Release liner – removed before application.

Mechanism of Drug Release

1. Drug release occurs mainly by diffusion
2. Follows Fick's law of diffusion
3. Release rate depends on:

- Polymer type and concentration
- Patch thickness
- Drug solubility
- Presence of penetration enhancers

Polymers Used in Matrix Patches

- HPMC
- Ethyl cellulose
- PVA
- PVP
- Eudragit RL/RS
- Chitosan

Advantages

Simple and economical to manufacture
Better flexibility and patient comfort
Lower risk of dose dumping compared to reservoir systems
Suitable for both hydrophilic and lipophilic drugs

Disadvantages

Difficult to achieve zero-order release

Drug release rate decreases over time
Limited drug loading capacity

Evaluation Parameters

Thickness uniformity
Weight variation
Drug content uniformity
Folding endurance
In-vitro drug release
Skin irritation study

Role of Patch Thickness in Matrix Patches

Thicker matrix → slower drug release
Thinner matrix → faster drug release
Uniform thickness ensures dose accuracy and controlled release

Examples

Nitroglycerin matrix patch
Diclofenac sodium matrix patch
Nicotine transdermal patch

4.2 Reservoir-Type Transdermal Patches

A reservoir-type transdermal patch is a system in which the drug is enclosed in a separate reservoir (liquid, gel, or suspension) and its release is controlled by a rate-controlling membrane before reaching the skin.

1. Structure and Components: -

1.1 Backing Layer

- Outermost protective layer
- Impermeable to drug, moisture, and oxygen
- Provides mechanical support
- Materials used: Polyethylene, Polyester, Aluminum-laminated films

1.2. Drug Reservoir

Contains drug in solution, suspension, or gel form May include:

- Solvent
- Penetration enhancers
- Stabilizers

Maintains constant drug activity throughout use

1.3. Rate-Controlling Membrane

- Controls drug diffusion rate

Determines release kinetics (often zero-order) Made of:

- Ethylene-vinyl acetate (EVA)
- Polyurethane
- Silicone membranes

Drug release depends mainly on membrane thickness and permeability, not on drug concentration.

1.4. Adhesive Layer

- Keeps patch attached to the skin
- Must be biocompatible and non-irritant
- Sometimes placed below or above the membrane

1.5. Release Liner

- Protects adhesive layer during storage
- Removed just before application.

❖ Mechanism of Drug Release

- Drug diffuses from the reservoir
- Passes through the rate-controlling membrane
- Enters the stratum corneum
- Reaches systemic circulation
- Release follows Fick's law of diffusion
- Often shows zero-order kinetics (constant release)

3. Factors Affecting Drug Release

- Membrane thickness
- Membrane permeability
- Drug concentration in reservoir
- Presence of penetration enhancers
- Skin condition

4. Advantages

- Precise and controlled drug release
- Can achieve zero-order release
- Suitable for potent drugs with short half-life
- Better control compared to matrix patches

5. Disadvantages

- Complex and costly manufacturing process
- Risk of dose dumping if membrane is damaged
- Less flexible and bulkier
- Not suitable for high-dose drugs

6. Evaluation Parameters

- Membrane integrity test
- Drug content uniformity
- In-vitro drug release study
- Adhesive strength
- Skin irritation test

Example

- Scopolamine transdermal patch
- Nitroglycerin reservoir patch
- Clonidine patch

4.3 Micro-Reservoir Transdermal Systems

A micro-reservoir transdermal system is a drug delivery system in which the drug is enclosed in microscopic reservoirs (micro-droplets or micro-spheres) that are uniformly dispersed within a polymeric matrix, and drug release is controlled by both diffusion and partitioning.

1. Concept and Principle

1.1 Drug is dissolved or dispersed in an aqueous phase.

1.2 This drug solution is dispersed as micro-reservoirs within a hydrophobic polymer matrix using high-shear mixing.

1.3. Each micro-reservoir acts as a miniature drug reservoir, but unlike classical reservoir systems, there is no single large reservoir.

2. Structure and Components

2.2. Backing Layer:-

- Protects patch from external environment
- Prevents drug loss and moisture entry
- Materials: Polyethylene, Polyester

2.3. Micro-Reservoir Drug System (Core Layer)

Drug present in micro-reservoirs

Drug may be in:-

1. Solution
2. Suspension

Micro-reservoirs are uniformly dispersed in polymer matrix Polymers used:-

- Silicone elastomers
- Polyisobutylene
- Ethylene-vinyl acetate (EVA)

3. Rate-Controlling Polymer Matrix

- Surrounds each micro-reservoir
- Controls diffusion of drug from micro-reservoirs to skin

4. Adhesive Layer

- Maintains contact with skin
- Often incorporated into the matrix itself

5. Release Liner

Removed before application

5.1. Mechanism of Drug Release

- Drug diffuses from micro-reservoirs
- Passes through the surrounding polymer matrix
- Penetrates the stratum corneum
- Enters systemic circulation

👉 Release is controlled by:

- Diffusion
- Partition coefficient
- Polymer permeability

5.2. Release Kinetics

- Near zero-order release
- More uniform than matrix systems
- Safer than reservoir systems (no dose dumping)

6. Advantages

- Combines benefits of matrix and reservoir systems

- Reduced risk of dose dumping
- Better control over drug release
- Improved drug stability
- Suitable for potent drugs

7. Disadvantages

- Complex manufacturing process
- Difficult to achieve uniform micro-reservoir size
- Higher production cost

8. Evaluation Parameters

- Patch thickness
- Micro-reservoir size and distribution
- Drug content uniformity
- In-vitro drug release
- Skin irritation test

9. Examples

- Nitroglycerin micro-reservoir patch
- Scopolamine micro-reservoir system



Fig 3: - Different types of transdermal patches.

5. Pharmaceutical Applications of Transdermal Drug Delivery System

Transdermal drug delivery systems (TDDS) have gained significant importance in pharmaceutical therapy due to their ability to provide controlled, sustained, and non-invasive drug administration. By delivering drugs through the skin directly into systemic circulation, TDDS overcome several limitations associated with oral and parenteral routes, such as gastrointestinal degradation, first-pass hepatic metabolism, and poor patient compliance. The applications of transdermal drug delivery extend across various therapeutic areas, particularly in chronic disease management where long-term and controlled drug release is required.

5.1 Pain Management

One of the most successful applications of TDDS is in the management of chronic and acute pain. Transdermal patches containing opioid and non-opioid analgesics provide sustained analgesic action over an extended period. Drugs such as fentanyl, buprenorphine, and diclofenac are commonly administered via transdermal patches. These patches maintain constant plasma drug levels, thereby reducing fluctuations that may cause side effects or inadequate pain control. Additionally, transdermal analgesic patches reduce gastrointestinal irritation and improve patient compliance, especially in patients requiring long-term pain management such as those with cancer or arthritis.[1-3]

5.2 Hormonal Replacement Therapy

Transdermal drug delivery is widely used in hormone replacement therapy due to its ability to provide steady hormone levels without first-pass metabolism. Hormones administered orally often undergo extensive hepatic metabolism, which may lead to reduced bioavailability and adverse effects. Transdermal patches containing estradiol, testosterone, and progesterone are commonly used in the management of menopausal symptoms, hypogonadism, and other endocrine disorders. The transdermal route ensures controlled hormone release,

improved therapeutic efficacy, and reduced risk of hepatic side effects compared to oral administration.[3]

5.3 Cardiovascular Disorders

TDDS plays an important role in the treatment of cardiovascular diseases, particularly in conditions requiring continuous drug delivery. Nitroglycerin transdermal patches are widely used in the prevention and management of angina pectoris. Transdermal delivery of nitroglycerin provides sustained vasodilation, reduces the frequency of anginal attacks, and avoids extensive first-pass metabolism. The ability to terminate therapy easily by removing the patch is an additional advantage in cardiovascular emergencies.[1-5]

5.4. Neurological and Central Nervous System Disorders

Transdermal drug delivery has shown promising results in the management of neurological disorders where continuous drug delivery is essential. Rotigotine transdermal patches are used in the treatment of Parkinson's disease to provide continuous dopaminergic stimulation. By maintaining constant plasma drug concentrations, transdermal systems help reduce motor fluctuations and improve patient compliance. TDDS also minimizes gastrointestinal side effects often associated with oral CNS medications.[3]

5.5. Smoking Cessation Therapy

Nicotine transdermal patches are one of the most widely used TDDS products. These patches deliver controlled amounts of nicotine over prolonged periods, helping to reduce withdrawal symptoms and cravings associated with smoking cessation. Transdermal nicotine therapy provides a safer alternative to smoking by eliminating exposure to harmful combustion products and improving patient adherence to cessation programs.[1]

5.6. Dermatological and Local Applications

TDDS is also used for local drug delivery in dermatological conditions such as inflammation, fungal infections, and psoriasis. In these applications, the drug primarily acts at the site of application, minimizing systemic exposure and side effects. Drugs such as lidocaine and ketoprofen are commonly formulated as transdermal or topical patches for localized therapeutic action.[2-5]

5.7. Anti-Motion Sickness Therapy

Transdermal patches containing scopolamine are widely used for the prevention of motion sickness. These patches provide prolonged drug release and are particularly useful during long-distance travel. The transdermal route offers improved patient convenience and reduces the need for repeated dosing compared to oral formulations.[3]

5.8. Emerging Applications and Future Therapeutic Use

Recent advances in transdermal technology have expanded its pharmaceutical applications beyond small molecules. Novel systems such as microneedle-based patches, iontophoretic systems, and smart transdermal patches have enabled the delivery of peptides, proteins, vaccines, and other macromolecules. These advanced transdermal systems hold great potential in personalized medicine, chronic disease management, and vaccination programs, highlighting the growing importance of TDDS in modern pharmaceutical therapy.[4-5]

6. Marketed Transdermal Patches

Several transdermal products are commercially available, demonstrating the clinical success of TDDS.

Drug	Indication	Patch type
Nitroglycerin	Angina pectoris	Reservoir
Nicotine	Smoking cessation	Matrix
Fentanyl	Chronic pain	Reservoir
Estradiol	Hormone replacement therapy	Matrix
Scopolamine	Motion sickness	Matrix

7. Recent Advances In Transdermal Drug Delivery System

Recent years have witnessed remarkable progress in transdermal drug delivery systems (TDDS), driven by advancements in material science, biotechnology, and pharmaceutical engineering. Conventional transdermal patches were primarily limited to low-molecular-weight, lipophilic drugs. However, modern approaches have significantly expanded the scope of TDDS to include macromolecules, peptides, proteins, and vaccines.

7.1 Microneedle-Based Transdermal Systems

Microneedle technology represents one of the most promising advances in TDDS. Microneedles are microscopic needles that painlessly penetrate the stratum corneum without reaching nerve endings, creating microchannels for drug transport. These systems improve the transdermal delivery of hydrophilic drugs, peptides, and vaccines while minimizing discomfort and infection risk. Microneedle patches have shown potential in insulin delivery, vaccination, and cancer therapy.

❖ Advantages:

- Minimally invasive
- Improved patient compliance
- Enhanced permeability

7.2 Iontophoresis

Iontophoresis is an electrically assisted transdermal drug delivery technique that uses a low-intensity electric current to enhance the penetration of charged drug molecules through the skin. This technique allows controlled and on-demand drug delivery, making it suitable for drugs requiring precise dosing. Iontophoretic systems have been investigated for the delivery of anti-inflammatory agents, local anesthetics, and peptides.

7.3 Sonophoresis

Sonophoresis employs low-frequency ultrasound waves to disrupt the lipid structure of the stratum corneum, thereby enhancing drug permeation. This technique increases skin permeability temporarily and is particularly useful for delivering high-molecular-weight drugs. Sonophoresis has been explored for transdermal delivery of proteins and anti-cancer agents.

7.4 Smart Transdermal Patches

Smart transdermal patches integrated with sensors and electronic components represent a major advancement in TDDS. These systems can monitor physiological parameters and adjust drug release accordingly. Wearable patches enable personalized therapy, improve patient adherence, and are particularly useful in chronic disease management.

Future Prospects Of Transdermal Drug Delivery

The future of transdermal drug delivery systems is highly promising due to continuous technological innovations and increasing demand for patient-friendly drug delivery methods. With ongoing research, TDDS is expected to overcome current limitations related to skin barrier properties and drug permeability.

➢ Delivery of Biologics and Macromolecules

Future research is focused on expanding TDDS to deliver biologics such as proteins, peptides, monoclonal antibodies, and nucleic acids. Advanced enhancement techniques like microneedles, electroporation, and nanocarriers are expected to make transdermal delivery of biologics clinically viable.

➢ Personalized and Precision Medicine

Smart transdermal systems will play a crucial role in personalized medicine by enabling dose adjustments based on patient-specific physiological parameters. Integration of biosensors with transdermal patches will allow real-time monitoring and feedback-controlled drug delivery.

➢ Vaccine Delivery

Transdermal patches have the potential to replace conventional injections for vaccination. Microneedle-based vaccine patches offer painless administration, improved stability, and ease of mass immunization, particularly in resource-limited settings.

- Combination Therapy

Future TDDS may be designed to deliver multiple drugs simultaneously, enabling combination therapy for chronic diseases such as diabetes, cardiovascular disorders, and neurological conditions.

- Improved Patient Compliance and Global Healthcare Impact

The ease of application, non-invasive nature, and reduced dosing frequency of TDDS will contribute to improved patient compliance and broader acceptance in global healthcare systems.

CONCLUSION

Based on the comprehensive analysis of the reviewed literature, it can be concluded that transdermal drug delivery systems (TDDS) represent a well-established and continuously evolving drug delivery approach in pharmaceutical sciences. The fundamental concept of TDDS lies in delivering drugs through the skin in a controlled manner to achieve systemic therapeutic effects while minimizing the limitations associated with conventional routes of administration. The reviewed studies clearly demonstrate that TDDS offer several advantages such as avoidance of first-pass metabolism, improved bioavailability, reduced dosing frequency, enhanced patient compliance, and better therapeutic outcomes, particularly in long-term and chronic therapies. The anatomical and physiological structure of the skin plays a crucial role in determining drug permeation. The stratum corneum acts as the primary barrier to transdermal drug absorption, and therefore, an in-depth understanding of skin anatomy and drug absorption pathways is essential for the successful design of transdermal formulations. The literature highlights that drug transport across the skin occurs mainly through transcellular, intercellular, and appendageal pathways, each contributing differently depending on the physicochemical properties of the drug and formulation strategy employed. The analysis of different types of transdermal patches, including matrix-type, reservoir-type, and micro-reservoir systems, indicates that formulation design significantly influences drug release behavior and therapeutic efficacy. The selection of polymers, plasticizers, penetration enhancers, and adhesives plays a key role in achieving optimal drug release and skin permeation. Pharmaceutical applications of TDDS have been well established in areas such as pain management, hormone replacement therapy, cardiovascular disorders, neurological diseases, smoking cessation, and dermatological conditions. The availability of marketed transdermal products further confirms the clinical reliability and patient acceptability of this drug delivery system. Recent advances discussed in the reviewed literature reveal that modern transdermal technologies have expanded the scope of TDDS beyond conventional small molecules. Innovative approaches such as microneedle-based systems, nano-carriers, iontophoresis, sonophoresis, and smart wearable patches have demonstrated the potential to overcome skin barrier limitations and enable the delivery of hydrophilic drugs, macromolecules, and biologics. These advancements indicate a shift of TDDS from traditional patch systems towards more sophisticated, patient-centric, and technology-driven delivery platforms. Furthermore, the growing global market for transdermal drug delivery systems reflects their increasing industrial and commercial relevance. Market analysis suggests a steady rise in demand driven by chronic disease prevalence, preference for non-invasive therapies, and technological innovation. This trend supports the long-term sustainability and future expansion of TDDS in pharmaceutical and healthcare sectors. In conclusion, transdermal drug delivery systems combine scientific innovation with clinical practicality, making them an important component of modern drug delivery strategies. Although certain challenges such as limited drug permeability and skin irritation still exist, continuous research and technological progress are expected to address these limitations. Overall, TDDS offer a promising, efficient, and patient-friendly drug delivery approach with significant potential for future pharmaceutical development and therapeutic applications.

REFERENCES

1. Rana R, Saroha K, Handa U, Kumar A, Nanda S. Transdermal patches as a tool for permeation of drug through skin. Journal of Chemical and Pharmaceutical Research. 2016;8(5):471–481.
2. Sharma N, Agarwal G, Rana AC. Transdermal drug delivery system: formulation, evaluation and

applications. International Journal of Chemical Engineering and Development. 2023;10(2):112–120.
3. Devi VK, Saisivam S, Maria GR, Deepti PU. Design and evaluation of matrix type transdermal patches. Journal of Pharmaceutical Research International. 2022;34(31):1–12.
4. Won Fen Wong, Gautam S, Chung Yeng Looi. Recent advances in transdermal drug delivery systems. Medicina. 2023;59(5):778.
5. Kumar S, Singh RP, Patel A. Transdermal drug delivery systems: principles, components and evaluation. Pharmaceutical Sciences Review. 2020;8(1):1–15.
6. Barry BW. Dermatological formulations: percutaneous absorption. Marcel Dekker Inc. 2001.
7. Hadgraft J. Skin, the final frontier. International Journal of Pharmaceutics. 2001; 224:1–18.
8. Elias PM. Stratum corneum architecture, metabolic activity and permeability. Journal of Investigative Dermatology. 1983; 80:44s–49s.
9. Walters KA. Dermal absorption and toxicity assessment. Marcel Dekker. 2008.
10. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Tropical Journal of Pharmaceutical Research. 2009;8(2):173–179.
11. Chien YW. Transdermal controlled systemic medications. Marcel Dekker Inc. 1987.
12. Robinson JR, Lee VH. Controlled drug delivery: fundamentals and applications. CRC Press. 2005.
13. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: a review. The Pharma Innovation Journal. 2012;1(4):66–75.
14. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology. 2008; 26:1261–1268.
15. Guy RH, Hadgraft J. Rate-limiting membranes in drug delivery. International Journal of Pharmaceutics. 1992;82: R1–R6.
16. Jain NK. Controlled and novel drug delivery. CBS Publishers. 2010.
17. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Current Drug Delivery. 2005; 2:23–33.
18. Trommer H, Neubert RHH. Overcoming the stratum corneum: the modulation of skin penetration. Skin Pharmacology and Physiology. 2006; 19:106–121.
19. Mitragotri S. Devices for overcoming biological barriers. Advanced Drug Delivery Reviews. 2013; 65:100–103.
20. Prausnitz MR. Microneedles for transdermal drug delivery. Advanced Drug Delivery Reviews. 2004; 56:581–587.
21. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems. Drug Delivery. 2006; 13:175–187.
22. Aqil M, Ali A. Monolithic matrix type transdermal drug delivery systems. Drug Development and Industrial Pharmacy. 2003; 29:1033–1039.
23. Shah VP, et al. In vitro release testing of transdermal systems. Pharmacopeial Forum. 1997; 23:4475–4484.
24. Raza K, et al. Transdermal drug delivery: a review. International Journal of Pharmaceutical Sciences Review and Research. 2015;30(1):16–25.
25. Larrañeta E, et al. Microneedles: a new frontier in transdermal drug delivery. Pharmaceutical Research. 2016; 33:1055–1073.
26. Donnelly RF, et al. Hydrogel-forming microneedle arrays. Advanced Functional Materials. 2012; 22:4879–4890.
27. Ita K. Transdermal delivery of vaccines. Recent Patents on Drug Delivery & Formulation. 2016; 10:35–40.
28. Kumar A, Pullakandam N, Prabu SL. Transdermal drug delivery system: an overview. International Journal of Pharmaceutical Sciences and Research. 2010; 1:49–54.
29. Aulton ME. Aulton's pharmaceutics: the design and manufacture of medicines. Churchill Livingstone. 2018.
30. Ansel HC, Allen LV, Popovich NG. Pharmaceutical calculations. Lippincott Williams & Wilkins. 2011.
31. FDA. Guidance for industry: transdermal delivery systems. U.S. Food and Drug Administration. 2011.
32. European Medicines Agency. Guideline on quality of transdermal patches. EMA. 2014.
33. Sharma N. A brief review on transdermal patches. Organic and Medicinal Chemistry International

Journal. 2018;7(2):1–8. DOI: 10.19080/OMCIJ.2018.07.555707
34. Shaikh N, Srivastava R. A review on transdermal drug delivery through patches. IP Indian Journal of Clinical and Experimental Dermatology. 2024;10(2):113–121. DOI: 10.18231/j.ijced.2024.022
35. Arora P, Mukherjee B. Design, development and evaluation of transdermal patches. International Journal of Pharmaceutics. 2002; 240:1–18.
36. Karande P, Mitragotri S. Enhancement of transdermal drug delivery via synergistic action. Journal of Controlled Release. 2009; 137:47–53.
37. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Advanced Drug Delivery Reviews. 2002;54: S41–S55.

Cite: Prerna Jagne*, Minakshi Warghane, A Review on Transdermal Drug Delivery System, Int. J. Med. Pharm. Sci., 2026, 2 (6), 155-168. https://doi.org/10.5281/zenodo.20676011